Appearing as a significant development in the fight against obesity, this medication is attracting considerable attention . It combines properties of two established GLP-1 receptor agonists, semaglutide , with an new glucose-dependent incretin component. Preliminary study data have demonstrated impressive fat loss in people with obesity , poten… Read More